Theranos Inc., the once-revered Silicon Valley medical startup, plans to challenge the revocation of its license to operate a California lab, among other sanctions federal regulators in Washington imposed after finding lax blood-testing practices.
In a statement released late Thursday, the company said it had filed a notice of intent to appeal the July decision. Still, Theranos said it hopes to keep settlement negotiations open with the Centers for Medicare and Medicaid Services, which regulates U.S. labs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
